

AGENDA
Uniform Formulary Beneficiary Advisory Panel
28 September 2005

<i>0700-0800</i>	Sign-in	Naval Heritage Center Theater, 701 Pennsylvania Ave N.W, Washington, D.C. 20004
<i>0800-0830</i>	Welcome and Opening Remarks	
	Meeting Rules	<ul style="list-style-type: none"> • Active participation by Panel only • Private Citizen comments restricted to first 12 sign-ups
	Meeting Objectives	<ul style="list-style-type: none"> • Discuss recommendations of the DoD P&T Committee meeting, 17-19 August 2005, San Antonio, TX. • Discuss drugs in the therapeutic classes of: Angiotensin Converting Enzyme Inhibitors, Calcium Channel Blockers, and Alpha Blockers for Benign Prostatic Hypertrophy. • Discuss prior authorization requirements for pramlintide injection. • Review Committee recommendations, make comments, and forward to the Director, TMA, for final decision to approve, disapprove, or modify the recommendations. • Entertain Private Citizen comments from 0830-0930. • Minutes of this meeting are being recorded and will be reduced to writing. All comments made here today are for the record and will be published.
<i>0830-0930</i>	Private Citizen Comments	<ul style="list-style-type: none"> • Up to twelve people who may have signed up to address the panel will be given a maximum of 5 minutes each using the microphone. Time limit will be strictly enforced. • This time is set aside for public comment only and product endorsements, presentations of marketing strategies, or comments from industry are not appropriate. • Any comments or questions during other times will not be acknowledged.
<i>0930-1000</i>	Break	
<i>1000-1130</i>	Present Angiotensin Converting Enzyme Inhibitor Drug Class Review	Ms. Angela Allerman / Maj Wade Tiller
	Panel Q & A	
	BAP Discussion	Ms. Sydney Hickey
	Vote / Comments	
<i>1130-1230</i>	Lunch	
<i>1230-1400</i>	Present Calcium Channel Blocker Drug Class Review	Ms. Angela Allerman / LtCol Dave Bennett
	Panel Q & A	
	BAP Discussion	Ms. Sydney Hickey
	Vote / Comments	
<i>1400-1430</i>	Break	
<i>1430-1530</i>	Present Alpha Blockers For Benign Prostatic Hypertrophy Drug Class Review	Maj Wade Tiller

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

	Panel Q & A	Ms. Sydney Hickey
	BAP Discussion	
	Vote / Comments	
<i>1530-1600</i>	Present Prior Authorization requirements for pramlintide (symlin) injection	LtCol Dave Bennett
	Panel Q & A	
	BAP Discussion	Sydney Hickey
	Vote / Comments	
<i>1600</i>	Wrap-up/Adjournment	MAJ Watson

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

0800-0830

1. Convene

The Department of Defense (DoD) Beneficiary Advisory Panel (BAP) will convene at 0800 hours on September 28, 2005 at the Naval Heritage Center Theater, 701 Pennsylvania Ave N.W, Washington, D.C. 20004.

2. Opening Remarks and welcome to panel members and audience

- Exits from the meeting room
- Restroom facilities
- Be courteous to your neighbor
- Lunch options on your own

3. Explanation of rules under which the BAP meeting will be conducted

- Only the Panel will actively participate in today's meeting
- Only the Panel will address questions to any briefer
- All audience comments and interaction will be confined to the 0830 – 0930 allotted time and then only to those designated and approved to address the panel as private citizens
- Private citizen comments submitted in writing

4. Beneficiary Advisory Panel members

John Class
Deborah Fryar
Marshall Hanson
Sydney Hickey
Rance Hutchings
Lisa LeGette
Jeffrey Lenow
Martha Miller
Charles Partridge
Jan Prasad
Robert Washington

5. Meeting objectives

0830 – 0930

6. Private Citizen comments

0930 - 1000

7. Break

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

1000 – 1130

8. Presentation of Angiotensin Converting Enzyme Inhibitor drug class review (Ms. Angela Allerman / Maj Wade Tiller)

- Relative Clinical Effectiveness
- Relative Cost Effectiveness
- UF Implementation Plan

9. Panel Q & A / Discussion of Angiotensin Converting Enzyme Inhibitors (Sydney Hickey)

10. Vote / Comments

1130 – 1230

11. Lunch

1230 - 1400

12. Presentation of Calcium Channel Blocker drug class review (Ms. Angela Allerman / LtCol Dave Bennett)

- Relative Clinical Effectiveness
- Relative Cost Effectiveness
- UF Implementation Plan

13. Panel Q & A / Discussion of Calcium Channel Blockers (Sydney Hickey)

14. Vote / Comments

1400 - 1430

15. Break

1430 – 1530

16. Presentation of Alpha Blockers for Benign Prostatic Hypertrophy drug class review (Maj Wade Tiller)

- Relative Clinical Effectiveness
- Relative Cost Effectiveness
- UF Implementation Plan

17. Panel Q & A / Discussion of Alpha Blockers for Benign Prostatic Hypertrophy (Sydney Hickey)

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

18. Vote / Comments

1530 – 1600

19. Presentation of PA requirements for pramlintide (Symlin) injection (LtCol Dave Bennett)

20. Panel Q & A / Discussion of PA requirements for pramlintide (Symlin) injection

21. Vote / Comments

1600

22. Wrap-up/Adjournment

*If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.